Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serological biomarkers of JIA-associated uveitis: ANA titers, ANA AC-30 staining pattern and prefoldin 5 antibodies.

Arthritis research & therapy·2026
Same author

International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Clinical Associations of Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease.

ACR open rheumatology·2026
Same author

Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies.

Rheumatology (Oxford, England)·2026
Same author

Interlaboratory variability in laboratory testing and reporting of myositis autoantibodies.

Journal of autoimmunity·2026
Same author

Striatin-3 is a human autoantigen but it is not associated with the S-phase G2 nuclear antigen (SG2NA) staining pattern.

Journal of autoimmunity·2025

Related Experiment Video

Updated: Jul 11, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Update on autoantibodies in systemic sclerosis.

Jennifer G Walker1, Marvin J Fritzler

  • 1Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.

Current Opinion in Rheumatology
|October 6, 2007
PubMed
Summary

Autoantibodies in systemic sclerosis (SSc) are linked to disease characteristics and prognosis. Newer autoantibodies offer insights into SSc pathogenesis and potential therapeutic strategies.

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis, vasculopathy, and immune system dysregulation.
  • Historically, research on SSc autoantibodies primarily focused on antinuclear antibodies (ANAs).
  • Recent advancements reveal the significance of autoantibodies targeting various cellular components beyond the nucleus.

Purpose of the Study:

  • To review autoantibodies associated with systemic sclerosis, with a focus on recent research findings.
  • To highlight the evolving understanding of autoantibodies beyond traditional nuclear targets in SSc.
  • To discuss the potential pathogenic roles and clinical implications of identified autoantibodies in SSc.

Main Methods:

  • Literature review of recent studies on autoantibodies in systemic sclerosis.

More Related Videos

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: Jul 11, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

  • Analysis of identified autoantibodies and their associations with clinical features.
  • Evaluation of emerging research on the pathogenic mechanisms and therapeutic potential of SSc-related autoantibodies.

    • Main Results:

    • Traditional autoantibodies like antitopoisomerase I and anticentromere antibodies remain significant in SSc.
    • Newer autoantibodies, including those targeting the platelet-derived growth factor receptor, are of particular interest due to their potential role in SSc pathogenesis.
    • Autoantibodies in SSc correlate with demographic, diagnostic, pathological, and prognostic aspects of the disease.

    Conclusions:

    • Autoantibodies are integral to understanding the multifaceted nature of systemic sclerosis.
    • Emerging autoantibodies provide novel insights into disease mechanisms and may represent future therapeutic targets.
    • Continued research into SSc autoantibodies is crucial for improving patient diagnosis, prognosis, and treatment.